A New Drug for Diabetes Redefines Treatment.. One Injection Weekly Instead of 7

SadaNews - The treatment for type 2 diabetes is witnessing a remarkable development with the emergence of a new drug called Awiqli, which is a long-acting insulin taken only once a week instead of the traditional daily injections.

This innovation, which has received approval from the U.S. Food and Drug Administration (FDA), may change the management of the disease for millions of patients around the world.

The drug relies on an effective substance that gradually releases insulin into the body, ensuring stable blood sugar levels throughout the week.

Its significance lies in simplifying the lives of patients, as it reduces the number of injections from 7 times a week to once, which may enhance adherence to treatment and alleviate the daily burden associated with diabetes.

Clinical Studies

The approval of the drug came after a series of clinical studies that demonstrated its effectiveness in reducing hemoglobin A1C levels, as announced by the U.S. Food and Drug Administration, which is the primary indicator for assessing diabetes control.

These studies included thousands of patients who used the drug alongside other treatments, whether oral medications or additional insulin related to meals.

Despite these positive results, the drug is not without side effects, as low blood sugar levels are the most prominent potential risks, along with injection site reactions, weight gain, and some skin changes. Doctors also warn of more serious complications such as severe allergies or effects on the heart in certain cases.

The use of Awiqli requires strict adherence to the doctor’s instructions, both in terms of dosing timing and injection method, with regular monitoring of blood sugar levels being necessary. Patients should also exercise caution when altering their lifestyle or medications, as this may affect the body's response to insulin.

While this treatment represents an advanced step towards simplifying diabetes management, experts emphasize that its success depends on correct use and ongoing medical follow-up, especially since its long-acting nature makes dose adjustments or handling emergencies more sensitive compared to traditional daily regimens.

Ultimately, this drug opens the door to a new phase in diabetes treatment, characterized by reduced complexity and increased flexibility, but with a need to maintain awareness and discipline to ensure the best health outcomes.